Get started
Live feed
SECFilingvia Quantisnow
TransCode Therapeutics Inc. logo

RNAZ: Amendment: TransCode Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Historical context for RNAZ

Across the 9 sessions after earlier RNAZ headlines, the stock closed higher 5 times and lower 3 times, with a median move of 2.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

RNAZ close-to-close change in the session after earlier headlines
SessionEarlier headlineRNAZSPY
Apr 27, 2026TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University+0.0%+0.2%
Apr 7, 2026TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028-2.9%+0.0%
Mar 3, 2026TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients+3.9%-0.9%
Feb 23, 2026TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development-0.2%-1.0%
Feb 5, 2026TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138+16.2%-1.2%
Jan 6, 2026TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma+0.7%+0.6%
Quantisnow market dataNASDAQ
TransCode Therapeutics Inc. logo
RNAZ
TransCode Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Listed since
2021
Get push alerts for RNAZ

Follow RNAZ and get a push notification the moment its next story breaks.

Full RNAZ profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RNAZ (TransCode Therapeutics Inc.) and more on Quantisnow.